Michael J. Higgins - 09 Jun 2026 Form 4 Insider Report for Voyager Therapeutics, Inc. (VYGR)

Reporting relationship: Director
Issuer ticker: VYGR
Reported as of: 09 Jun 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 11 Jun 2026, 16:03:21 UTC
Prior SEC filing: 27 Jun 2025
Source filing: View source filing
Reporting owner signature: /s/ Gregory L. Shiferman, as Attorney-in-Fact for Michael J. Higgins

Key filing fact

Michael J. Higgins filed Form 4 for Voyager Therapeutics, Inc. (VYGR) on 11 Jun 2026.

Key facts

This page summarizes Michael J. Higgins's Form 4 filing for Voyager Therapeutics, Inc. (VYGR).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 11 Jun 2026, 16:03.

Change

Previous filing in this sequence was filed on 27 Jun 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001478521 Primary reporting owner

Higgins Michael J

Relationship: Director
Address: C/O VOYAGER THERAPEUTICS, INC., 75 HAYDEN AVENUE, LEXINGTON
Signature: /s/ Gregory L. Shiferman, as Attorney-in-Fact for Michael J. Higgins
Signature date: 11 Jun 2026

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

VYGR transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value
Shares: +30,000
Change %
Price: $0.000000^*
Shares after: 30,000
Date: 09 Jun 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 30,000
Exercise price: $3.43
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

This stock option was issued pursuant to the 2025 Stock Incentive Plan of Voyager Therapeutics, Inc. in accordance with its director compensation policy. The vesting commencement date (the "Vesting Commencement Date") of the option is the grant date. All of the shares of common stock underlying the option vest upon the earlier of the one-year anniversary of the Vesting Commencement Date or the date of the next annual meeting of stockholders, in each case subject to the Reporting Person's continued service as a director.

SEC remarks

Exhibit 24: Power of Attorney